Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2017
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 23, 2017
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2017
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastroesophageal Junction Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 21, 2017
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Centre Léon Bérard | Fox Chase Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of D842V/PDGFRA-mutated with Gastrointestinal Stromal Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2016
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Centre Léon Bérard | Fox Chase Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2015
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2015
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 05, 2014
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Arog Pharmaceuticals | Ohio State University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2014
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Arog Pharmaceuticals | Ohio State University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Arog Pharmaceuticals | The V Foundation for Cancer Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Crenolanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2011
Lead Product(s) : Crenolanib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Arog Pharmaceuticals | The V Foundation for Cancer Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
